Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Leukemia

  Free Subscription


13.08.2018

1 Acta Haematol
2 Am J Hematol
4 Ann Hematol
1 Biochem Biophys Res Commun
1 BMC Cancer
2 Bone Marrow Transplant
2 Eur J Haematol
2 Exp Hematol
2 Int J Hematol
1 J Immunol
3 J Pediatr Hematol Oncol
1 Leuk Res
4 Leukemia
2 PLoS One


   Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Acta Haematol

  1. ABOU DALLE I, Cortes JE, Pinnamaneni P, Lamothe B, et al
    A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia.
    Acta Haematol. 2018;140:30-39.
    PubMed     Text format     Abstract available


    Am J Hematol

  2. O'BRIEN S, Patel M, Kahl BS, Horwitz SM, et al
    Duvelisib, an oral dual PI3K-delta,gamma inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a Phase 1 study.
    Am J Hematol. 2018 Aug 10. doi: 10.1002/ajh.25243.
    PubMed     Text format     Abstract available

  3. ABAZA Y, Cortes J, Ravandi F, Kadia T, et al
    Prognostic significance of hyperdiploidy in adult acute myeloid leukemia.
    Am J Hematol. 2018 Aug 3. doi: 10.1002/ajh.25240.
    PubMed     Text format     Abstract available


    Ann Hematol

  4. DE ALVARENGA EC, Silva WN, Vasconcellos R, Paredes-Gamero EJ, et al
    Promyelocytic leukemia protein in mesenchymal stem cells is essential for leukemia progression.
    Ann Hematol. 2018 Aug 1. pii: 10.1007/s00277-018-3463.
    PubMed     Text format     Abstract available

  5. WANG H, Li Y, Lv N, Li Y, et al
    Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes.
    Ann Hematol. 2018 Aug 6. pii: 10.1007/s00277-018-3464.
    PubMed     Text format     Abstract available

  6. SCHULER E, Zadrozny N, Blum S, Schroeder T, et al
    Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapy.
    Ann Hematol. 2018 Aug 4. pii: 10.1007/s00277-018-3466.
    PubMed     Text format     Abstract available

  7. XIAO H, Li L, Pang Y, Wu Y, et al
    Sequential treatment combining cladribine-based re-induction, myeloablative allogeneic HSCT, and prophylactic donor lymphocyte infusion: a promising treatment for refractory acute myeloid leukemia.
    Ann Hematol. 2018 Aug 4. pii: 10.1007/s00277-018-3453.
    PubMed     Text format     Abstract available


    Biochem Biophys Res Commun

  8. WANG K, Wang C, Zhu CJ, Li G, et al
    4-Amino-2-Trifluoromethyl-Phenyl Retinate induced leukemia cell differentiation by decreasing eIF6.
    Biochem Biophys Res Commun. 2018 Aug 2. pii: S0006-291X(18)31657.
    PubMed     Text format     Abstract available


    BMC Cancer

  9. YU L, Wang H, Milijkovic D, Huang X, et al
    Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study.
    BMC Cancer. 2018;18:782.
    PubMed     Text format     Abstract available


    Bone Marrow Transplant

  10. SHETH V, Labopin M, Canaani J, Volin L, et al
    Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis.
    Bone Marrow Transplant. 2018 Aug 7. pii: 10.1038/s41409-018-0288.
    PubMed     Text format     Abstract available

  11. CHO C, Hsu M, Barba P, Maloy MA, et al
    Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis.
    Bone Marrow Transplant. 2017 Oct 9. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


    Eur J Haematol

  12. LAM TS, van de Meent M, Marijt EWA, Falkenburg JHF, et al
    Immune surveillance by autoreactive CD4 positive helper T-cells is a common phenomenon in patients with acute myeloid leukemia.
    Eur J Haematol. 2018 Aug 4. doi: 10.1111/ejh.13157.
    PubMed     Text format     Abstract available

  13. KHALIL MMI, Lipton JH, Atenafu EG, Gupta V, et al
    Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia.
    Eur J Haematol. 2018;100:198-205.
    PubMed     Text format     Abstract available


    Exp Hematol

  14. KOTB A, Fakih RE, Hanbali A, Hawsawi Y, et al
    Philadelphia-Like Acute Lymphoblastic Leukemia: Diagnostic dilemma and management perspectives.
    Exp Hematol. 2018 Jul 31. pii: S0301-472X(18)30743.
    PubMed     Text format     Abstract available

  15. BORGES CS, Ferreira AF, Almeida VH, Gomes FG, et al
    CROSSTALK BETWEEN BCR-ABL AND PROTEASE-ACTIVATED RECEPTOR 1 (PAR1) SUGGESTS A NOVEL TARGET IN CHRONIC MYELOID LEUKEMIA.
    Exp Hematol. 2018 Aug 1. pii: S0301-472X(18)30746.
    PubMed     Text format     Abstract available


    Int J Hematol

  16. CHIBA A, Toya T, Mizuno H, Tokushige J, et al
    Chronic myelogenous leukemia presenting with central nervous system infiltration, successfully treated with central nervous system-directed chemotherapy followed by allogeneic stem cell transplantation.
    Int J Hematol. 2018 Aug 4. pii: 10.1007/s12185-018-2511.
    PubMed     Text format     Abstract available

  17. ISHIKAWA J, Matsumura I, Kawaguchi T, Kuroda J, et al
    Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial).
    Int J Hematol. 2018;107:535-540.
    PubMed     Text format     Abstract available


    J Immunol

  18. GUPTA R, Yan XJ, Barrientos J, Kolitz JE, et al
    Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion.
    J Immunol. 2018 Aug 1. pii: jimmunol.1800591. doi: 10.4049/jimmunol.1800591.
    PubMed     Text format     Abstract available


    J Pediatr Hematol Oncol

  19. RAJPURKAR M, Alonzo TA, Wang YC, Gerbing RB, et al
    Risk Markers for Significant Bleeding and Thrombosis in Pediatric Acute Promyelocytic Leukemia; Report From the Children's Oncology Group Study AAML0631.
    J Pediatr Hematol Oncol. 2018 Aug 8. doi: 10.1097/MPH.0000000000001280.
    PubMed     Text format     Abstract available

  20. REINECKE J, Lowas S, Snowden J, Neemann K, et al
    Blood Stream Infections and Antibiotic Utilization in Pediatric Leukemia Patients With Febrile Neutropenia.
    J Pediatr Hematol Oncol. 2018 Aug 8. doi: 10.1097/MPH.0000000000001279.
    PubMed     Text format     Abstract available

  21. BELLE FN, Kasteler R
    Risk Factors and the Prevention of Weight Gain During Induction Chemotherapy in Children With Acute Lymphoblastic Leukemia.
    J Pediatr Hematol Oncol. 2018 Aug 4. doi: 10.1097/MPH.0000000000001286.
    PubMed     Text format    


    Leuk Res

  22. DARVISHI M, Mashati P, Khosravi A
    The clinical significance of CDX2 in leukemia: A new perspective for leukemia research.
    Leuk Res. 2018;72:45-51.
    PubMed     Text format     Abstract available


    Leukemia

  23. KURTZ SE, Eide CA, Kaempf A, Mori M, et al
    Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia.
    Leukemia. 2018 Aug 6. pii: 10.1038/s41375-018-0225.
    PubMed     Text format    

  24. PATNAIK MM, Tefferi A, Garcia-Manero G
    Blast-phase chronic myelomonocytic leukemia: more than just semantics.
    Leukemia. 2018 Aug 7. pii: 10.1038/s41375-018-0228.
    PubMed     Text format    

  25. DUPLOYEZ N, Marceau-Renaut A, Villenet C, Petit A, et al
    The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia.
    Leukemia. 2018 Aug 8. pii: 10.1038/s41375-018-0227.
    PubMed     Text format     Abstract available

  26. TAKESHITA A, Asou N, Atsuta Y, Sakura T, et al
    Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study.
    Leukemia. 2018 Aug 9. pii: 10.1038/s41375-018-0233.
    PubMed     Text format     Abstract available


    PLoS One

  27. GENTIL M, Hugues P, Desterke C, Telliam G, et al
    Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML).
    PLoS One. 2018;13:e0200923.
    PubMed     Text format     Abstract available

  28. GRUNDY M, Jones T, Elmi L, Hall M, et al
    Early changes in rpS6 phosphorylation and BH3 profiling predict response to chemotherapy in AML cells.
    PLoS One. 2018;13:e0196805.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: